Drug profile · INN
daxibotulinumtoxina-lanm
DAXXIFY
daxibotulinumtoxina-lanm (DAXXIFY) is a synaptosomal nerve-associated protein 25 (snap-25) inhibitor. Route of administration: intramuscular, subcutaneous. Current US regulatory status: approved.
Drug details — daxibotulinumtoxina-lanm
- US status
- approved
- Class
- —
- Route
- INTRAMUSCULAR, SUBCUTANEOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
daxibotulinumtoxina-lanm (DAXXIFY) is a synaptosomal nerve-associated protein 25 (snap-25) inhibitor. Route of administration: intramuscular, subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
Primary target: Synaptosomal-associated protein 25
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is daxibotulinumtoxina-lanm?
daxibotulinumtoxina-lanm (DAXXIFY) is a synaptosomal nerve-associated protein 25 (snap-25) inhibitor. Route of administration: intramuscular, subcutaneous. Current US regulatory status: approved.
What is the brand name for daxibotulinumtoxina-lanm?
DAXXIFY is a marketed brand name for daxibotulinumtoxina-lanm. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of daxibotulinumtoxina-lanm?
daxibotulinumtoxina-lanm has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.